1067 related articles for article (PubMed ID: 15105283)
1. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
2. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
[TBL] [Abstract][Full Text] [Related]
4. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Witherow FN; Helmy A; Webb DJ; Fox KA; Newby DE
Circulation; 2001 Oct; 104(18):2177-81. PubMed ID: 11684627
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature.
Ritter JM; Cockcroft JR; Sciberras DG; Goldberg MR
J Hypertens Suppl; 1993 Apr; 11(3):S59-61. PubMed ID: 8391072
[TBL] [Abstract][Full Text] [Related]
7. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure.
Jorde UP; Vittorio TJ; Dimayuga CA; Homma S; Rizkala A; Le Jemtel TH; Katz SD
Am J Cardiol; 2004 Dec; 94(12):1501-5. PubMed ID: 15589004
[TBL] [Abstract][Full Text] [Related]
8. Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure.
Davie AP; Rumley A; Lowe GD; McMurray JJ
Thromb Haemost; 2001 Dec; 86(6):1585-6. PubMed ID: 11776334
[No Abstract] [Full Text] [Related]
9. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure.
Davie AP; Dargie HJ; McMurray JJ
Circulation; 1999 Jul; 100(3):268-73. PubMed ID: 10411851
[TBL] [Abstract][Full Text] [Related]
10. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
[TBL] [Abstract][Full Text] [Related]
11. Vascular B1 kinin receptors in patients with congestive heart failure.
Lang NN; Cruden NL; Tse GH; Bloomfield P; Ludlam CA; Fox KA; Newby DE
J Cardiovasc Pharmacol; 2008 Nov; 52(5):438-44. PubMed ID: 19033823
[TBL] [Abstract][Full Text] [Related]
12. Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition.
Juhlin T; Erhardt LR; Ottosson H; Jönsson BA; Höglund P
Eur J Heart Fail; 2007 Feb; 9(2):191-6. PubMed ID: 16859993
[TBL] [Abstract][Full Text] [Related]
13. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
van Wijngaarden J; Smit AJ; de Graeff PA; van Gilst WH; van der Broek SA; van Veldhuisen DJ; Lie KI; Wesseling H
J Cardiovasc Pharmacol; 1994 Feb; 23(2):240-5. PubMed ID: 7511753
[TBL] [Abstract][Full Text] [Related]
14. [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure].
Vizir VA; Berezin AE
Ter Arkh; 2002; 74(1):52-5. PubMed ID: 11878061
[TBL] [Abstract][Full Text] [Related]
15. Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure.
Binkley PF; Nunziata E; Haas GJ; Starling RC; Leier CV; Cody RJ
Am Heart J; 2000 Jul; 140(1):34-42. PubMed ID: 10874261
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
Goldberg MR; de Mey C; Wroblewski JM; Li Q; Schroeter V; Belz GG
Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
[TBL] [Abstract][Full Text] [Related]
17. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
[TBL] [Abstract][Full Text] [Related]
18. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure.
Dickstein K; Gottlieb S; Fleck E; Kostis J; Levine B; DeKock M; LeJemtel T
J Hypertens Suppl; 1994 Jul; 12(2):S31-5. PubMed ID: 7965263
[TBL] [Abstract][Full Text] [Related]
20. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.
Nielsen S; Dollerup J; Nielsen B; Jensen HA; Mogensen CE
Nephrol Dial Transplant; 1997; 12 Suppl 2():19-23. PubMed ID: 9269694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
